divider

News and Media

Publications and resources for members of the press.

divider

News

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]

Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences

NEW YORK and TOKYO October 2, 2022 — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction  with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), announced today it has  submitted a non-binding proposal (the “Proposal”) to the Audit Committee of the Board of Directors  (the “Audit Committee”) of Myovant Sciences Ltd. (“Myovant”) offering to acquire all outstanding […]

Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022

July 27, 2022 at 4:05 PM EDT First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022 Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in […]

divider

Publications

Economic burden of congenital athymia in the United States for patients receiving supportive care during the first 3 years of life

Congenital athymia is an ultra-rare pediatric condition characterized by the lack of thymus in utero and the naïve T cells critical for infection defense and immune regulation.

ELEVATE 2: A Multicenter Study of Rodatristat Ethyl in Patients with WHO Group 1 Pulmonary Arterial Hypertension

Rodatristat ethyl is a first in class prodrug for rodatristat, a potent inhibitor of tryptophan hydroxylase, the rate limiting enzyme in the biosynthesis of serotonin from dietary tryptophan.

Defining the Clinical, Emotional, Social, and Financial Burden of Congenital Athymia

This cross-sectional study of adult caregivers of patients with congenital athymia used both a quantitative survey and qualitative interviews. Caregivers of patients currently receiving supportive care responded to questions about the past 12 months.

About Us

United in our mission to deliver breakthrough medicines to patients faster, we make Sumitovant greater than the sum of our parts.

Get to Know Us

News from Sumitovant Portfolio Companies